Phaseline

Companies › Oculis

Oculis: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Ophthalmology, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Privosegtor (OCS-05)
Neuroprotective candidate
–Phase 3Optic NeuritisDec 2027
licaminlimab
Anti-ICAM-1 antibody
ICAM1Phase 2Dry Eye Disease (DED)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07548632licaminlimabPhase 2Dry Eye Disease (DED)OphthalmologyDec 2026
NCT07623668Privosegtor (OCS-05)Phase 3Optic NeuritisNeurologyDec 2027

From the company's SEC filings

Cash and short-term investments of 82m CHF on 2025-12-31; operating cash outflow about 66m CHF a year; runway about 15 months at that burn, to Mar 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Targets

ICAM1 (1)

Companies with the same targets

–

Companies built like this

Annexon Immunovant Sciences Coya Therapeutics NervGen Pharma Cognition Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.